The supply of initial 200 million doses of BNT162b2, the COVID-19 vaccine manufactured by Pfizer Inc (NYSE:PFE) and BioNTech SE (Nasdaq:BNTX), is anticipated to be finalized by September 2021 across Europe, according to some media reports.
Meanwhile, Most European countries have already started inoculating healthcare workers and vulnerable people with the Pfizer-BioNTech vaccine.
Furthermore, the European Union has signed advance buying agreements with Pfizer-BioNTech, AstraZeneca, CureVac, J&J, Moderna, and Sanofi for a total of almost 2 billion doses.
However, the media reports say that discussions are ongoing regarding the delivery of a further 100 million doses and had not been concluded yet.
On 10 December 2020, the US Food and Drug Administration (FDA) had granted the EUA (emergency use authorization) to Pfizer-BioNTech’s COVID-19 Vaccine in the U.S.
Lately, the government of the United States had ordered additional 100 million shots of BNT162b2, bringing total doses for the nation to 200 million.